129 related articles for article (PubMed ID: 20673183)
1. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.
Xu HR; Chen WL; Li XN; Chu NN
Pharm Biol; 2010 Aug; 48(8):947-52. PubMed ID: 20673183
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.
Zhang D; Wang X; Yang M; Wang G; Liu H
Xenobiotica; 2011 Jun; 41(6):511-7. PubMed ID: 21521077
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects.
Zhang D; Yang M; Liu M; Zhang Y; Wang X; Xiao X; Liu H
Xenobiotica; 2012 Nov; 42(11):1156-62. PubMed ID: 22612620
[TBL] [Abstract][Full Text] [Related]
6. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
[TBL] [Abstract][Full Text] [Related]
7. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects.
Zhang D; Zhang Y; Liu M; Wang X; Yang M; Han J; Liu H
Eur J Drug Metab Pharmacokinet; 2013 Sep; 38(3):209-15. PubMed ID: 23229306
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole.
Zalloum I; Hakooz N; Arafat T
Mol Biol Rep; 2012 Apr; 39(4):4195-200. PubMed ID: 21769476
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.
Gumus E; Karaca O; Babaoglu MO; Baysoy G; Balamtekin N; Demir H; Uslu N; Bozkurt A; Yuce A; Yasar U
Eur J Clin Pharmacol; 2012 May; 68(5):629-36. PubMed ID: 22076562
[TBL] [Abstract][Full Text] [Related]
13. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication.
Ward MB; Foster DJ
Eur J Clin Pharmacol; 2011 Mar; 67(3):261-6. PubMed ID: 21079935
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males.
Sakurai Y; Hirayama M; Hashimoto M; Tanaka T; Hasegawa S; Irie S; Ashida K; Kayano Y; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2007 Dec; 30(12):2238-43. PubMed ID: 18057705
[TBL] [Abstract][Full Text] [Related]
16. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
Lima JJ; Lang JE; Mougey EB; Blake KB; Gong Y; Holbrook JT; Wise RA; Teague WG
J Pediatr; 2013 Sep; 163(3):686-91. PubMed ID: 23623526
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
Niioka T; Miura M; Uno T; Yasui-Furukori N; Hayakari M; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2008 May; 64(5):503-9. PubMed ID: 18224311
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
Cho H; Choi MK; Cho DY; Yeo CW; Jeong HE; Shon JH; Lee JY; Shin JS; Cho M; Kim DY; Shin JG
J Clin Pharmacol; 2012 Jul; 52(7):976-84. PubMed ID: 21593280
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
20. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
